The global immune checkpoint inhibitors market size reached US$ 43.1 billion in 2023. The market is projected to reach US$ 157.2 billion by 2032, exhibiting a growth rate (CAGR) of 15.47% during 2023-2032. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.
Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.
2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2024-2032?
3. What are the key factors driving the global immune checkpoint inhibitors market?
4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?
5. What is the breakup of the global immune checkpoint inhibitors market based on the type?
6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?
7. What is the breakup of the global immune checkpoint inhibitors market based on the application?
8. What are the key regions in the global immune checkpoint inhibitors market?
9. Who are the key players/companies in the global immune checkpoint inhibitors market?
Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.
Immune Checkpoint Inhibitors Market Trends
The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.Key Market Segmentation:
The report provides an analysis of the key trends in each segment of the global immune checkpoint inhibitors market, along with forecasts at the global, regional, and country levels from 2023-2032. The report has categorized the market based on type, distribution channel, and application.Type Insights:
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Application Insights:
- Lung Cancer
- Bladder Cancer
- Melanoma
- Colorectal Cancer
- Hodgkin Lymphoma
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc.Key Questions Answered in This Report
1. How big is the global immune checkpoint inhibitors market?2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2024-2032?
3. What are the key factors driving the global immune checkpoint inhibitors market?
4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?
5. What is the breakup of the global immune checkpoint inhibitors market based on the type?
6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?
7. What is the breakup of the global immune checkpoint inhibitors market based on the application?
8. What are the key regions in the global immune checkpoint inhibitors market?
9. Who are the key players/companies in the global immune checkpoint inhibitors market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Immune Checkpoint Inhibitors Market
6 Market Breakup by Type
7 Market Breakup by Distribution Channel
8 Market Breakup by Application
9 Market Breakup by Region
10 Drivers, Restraints, and Opportunities
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AstraZeneca plc
- Bristol-Myers Squibb Company
- GSK plc
- Merck & Co. Inc.
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Seagen Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | January 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 43.1 Billion |
| Forecasted Market Value ( USD | $ 157.2 Billion |
| Compound Annual Growth Rate | 15.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
